Access breakthrough clinical trials, expert care, and one-on-one patient support all in one place.
This study will be a randomized, active-control study that will help to determine if Sparsentan is effective at improving symptoms of IgAN.
This study will examine the effectiveness of Acthar® Gel in adults subjects with FSGS who have failed to achieve remission with, or who are intolerant of, 1 or more previous immunosuppressive therapies.
This clinical trial will determine the effectiveness of Sparsentan at reducing proteinuria in patients with primary FSGS.
Join 2 million participants for a healthier life
Definitely consider the trials. It's so exciting that pharma is finally putting money into FSGS, and we have to participate to help find a cure! I've already participated in one and it was easy and painless.